LONDON and HONG KONG, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14 to February 16, 2023.
About Prenetics
Founded in 2014, Prenetics is a major global diagnostic and genetic testing company with the mission to bring health closer to millions of people globally and decentralize healthcare by making the three pillars — Consumer Health, Clinical Care and Medical & Cancer Genomics — comprehensive and accessible to anyone, at anytime and anywhere. Prenetics is led by visionary entrepreneur, Danny Yeung, with operations across nine locations, including The United Kingdom, Hong Kong, India, South Africa, and Southeast Asia. Prenetics develops consumer genetic testing and early colorectal cancer screening and provides COVID-19 testing, rapid point of care and at-home diagnostic testing and medical genetic testing. Prenetics is listed on NASDAQ with the ticker PRE. To learn more about Prenetics, visit www.prenetics.com.
| Investor Relations Contact: | ||
| This email address is being protected from spambots. You need JavaScript enabled to view it. | ||
| ICR Westwicke: | ||
| Caroline Corner | +415 202 5678 | Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Media contact: | ||
| Strategic Public Relations Group | ||
| Corinne Ho | +852 2114 4911 | Email: This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$13.99 |
| Daily Change: | 0.10 0.72 |
| Daily Volume: | 121,300 |
| Market Cap: | US$160.190M |
October 08, 2025 September 12, 2025 June 18, 2025 June 12, 2025 March 05, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
